Business Context and Reporting Period
This Form 8-K filing by Pavmed Inc. (PAVM) is dated June 28, 2023. The report addresses a regulatory event concerning the company's listing status on The Nasdaq Stock Market.
Key Financial Metrics
The filing text does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on listing compliance status.
Material Changes and Events
- Nasdaq Compliance Extension: On June 28, 2023, Nasdaq granted Pavmed an additional 180 calendar days (until December 26, 2023) to regain compliance with the minimum bid price requirement.
- Background: The company previously failed to meet the $1.00 per share minimum bid price for 30 consecutive business days ending December 28, 2022. The initial 180-day compliance period expired on June 27, 2023, without the company regaining compliance.
- Compliance Requirement: To maintain listing, the closing bid price must reach at least $1.00 per share for a minimum of ten consecutive business days within the new 180-day window.
- Trading Status: The notification has no immediate effect on trading; common stock (PAVM) and Series Z warrants (PAVMZ) continue to trade uninterrupted.
Outlook, Risks, and Management Commentary
Management intends to consider all available options to regain compliance with Nasdaq listing standards. The primary risk identified is the potential delisting if the company fails to meet the $1.00 minimum bid price requirement by the December 26, 2023 deadline.
Investor Verification Checklist
- Verify the current closing bid price of PAVM common stock relative to the $1.00 threshold.
- Monitor the company's progress toward achieving ten consecutive days of compliance before December 26, 2023.
- Review subsequent filings for any announcements regarding reverse stock splits or other capital structure changes intended to address the bid price deficiency.
- Confirm that trading remains uninterrupted on The Nasdaq Capital Market.